Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Evaluering i den virkelige verden af ​​HistoSonics Edison-systemet til behandling af levertumorer på tværs af multidisciplinære brugere (BOOMBOX: Master Study)

3. november 2026 opdateret af: HistoSonics, Inc.

The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristics may affect histotripsy success at 36 hours post-histotripsy procedure. Sub-studies to the BOOMBOX: Master Study will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any participant enrolled in the BOOMBOX: Master Study that also qualifies for a sub-study may enroll in the sub-study in parallel; sub-studies will be described in separate sub-study protocols. The BOOMBOX: Master Study will collect information about participants before, during, and after the histotripsy treatment procedure. All participants will be followed per standard clinical follow-up based on each site's clinical practice for up to 5 years after the initial histotripsy procedure or until completion of their follow-up in a sub-study, whichever is longer.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

BOOMBOX: Master Study is an observational, single arm, non-randomized, prospective master study. Following histotripsy treatment of liver tumor(s), subjects will undergo imaging ≤36 hours post-histotripsy treatment procedure to determine histotripsy success. Subjects will then be followed per standard clinical follow-up as determined at each site with regular review of adverse event data for up to 5 years or until completion of their follow-up in a sub-study, whichever is longer.

As an observational study, the master protocol does not direct the use of the HistoSonics Edison System towards any specific clinical intent or any specific disease state. Rather, it will uniformly enroll patients and capture real-world standard-of-care data on the usage of the HistoSonics Edison System as implemented by the treating physician on all subjects treated with histotripsy that meet the study criteria and agree to participate in the study. Sub-studies to the master protocol will investigate specific populations and/or clinical questions with more stringent enrollment criteria, standardized testing criteria, and/or follow-up schedule. Any subject enrolled in the master study who also qualifies for a sub-study may enroll in the sub-study in parallel to the master study.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

5000

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Alabama
    • California
      • Fullerton, California, Forenede Stater, 92835
      • Los Angeles, California, Forenede Stater, 90048
        • Rekruttering
        • Cedars-Sinai Medical Center
        • Ledende efterforsker:
          • Nicholas Nissen, MD
        • Kontakt:
      • Mission Viejo, California, Forenede Stater, 92691
      • Newport Beach, California, Forenede Stater, 92663
        • Rekruttering
        • Hoag
        • Ledende efterforsker:
          • Trushar Patel, MD
        • Kontakt:
      • San Francisco, California, Forenede Stater, 94107
        • Rekruttering
        • Sutter Bay Hospitals
        • Kontakt:
        • Ledende efterforsker:
          • Casey Ward, MD
      • Santa Monica, California, Forenede Stater, 90404
        • Rekruttering
        • Providence Saint John's Health Center
        • Kontakt:
        • Ledende efterforsker:
          • Paul Shin, MD
    • Florida
      • Altamonte Springs, Florida, Forenede Stater, 32701
        • Trukket tilbage
        • AdventHealth Altamonte Springs
      • Celebration, Florida, Forenede Stater, 34747
      • Fort Myers, Florida, Forenede Stater, 33905
        • Rekruttering
        • Lee Health Cancer Institute
        • Ledende efterforsker:
          • Mark Bloomston, MD
        • Kontakt:
      • Miami, Florida, Forenede Stater, 33176
        • Trukket tilbage
        • Baptist Health Miami Cardiac & Vascular Institute
    • Georgia
      • Gainesville, Georgia, Forenede Stater, 30501
        • Rekruttering
        • Northeast Georgia Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Terence Jackson, MD
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • RUSH University Medical Center
        • Ledende efterforsker:
          • Jordan Tasse, MD
        • Kontakt:
    • Louisiana
      • Shreveport, Louisiana, Forenede Stater, 71103
        • Rekruttering
        • Willis Knighton Health
        • Kontakt:
        • Ledende efterforsker:
          • Gazi Zibari, MD
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21205
        • Rekruttering
        • Johns Hopkins Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Cristos Georgiades, MD, PhD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Mass General Brigham
        • Kontakt:
        • Ledende efterforsker:
          • Jiping Wang, MD, PhD
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Rekruttering
        • Henry Ford Health
        • Kontakt:
        • Ledende efterforsker:
          • Atsushi Yoshida, MD
      • Wyoming, Michigan, Forenede Stater, 49519
        • Rekruttering
        • University of Michigan Health - West
        • Kontakt:
        • Ledende efterforsker:
          • Michael Koets, MD
    • Nevada
      • Reno, Nevada, Forenede Stater, 89502
        • Rekruttering
        • Renown Regional Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Nick Manguso, MD
    • New York
      • Manhasset, New York, Forenede Stater, 11030
        • Rekruttering
        • Northwell Health
        • Kontakt:
        • Ledende efterforsker:
          • Laurence Lau, MD
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Weill Cornell Medicine
        • Kontakt:
        • Ledende efterforsker:
          • Juan Rocca, MD
      • New York, New York, Forenede Stater, 10016
      • New York, New York, Forenede Stater, 10065
        • Rekruttering
        • Memorial Sloan Kettering Cancer Center
        • Kontakt:
        • Ledende efterforsker:
          • Vlasios Sotirchos, MD
        • Ledende efterforsker:
          • Constantinos Sofocleous, MD, PhD
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • Columbia University Irving Medical Center
        • Ledende efterforsker:
          • Stephen Reis, MD
        • Kontakt:
      • Rochester, New York, Forenede Stater, 14642
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27103
    • Ohio
      • Centerville, Ohio, Forenede Stater, 45459
        • Rekruttering
        • Miami Valley Hospital South
        • Ledende efterforsker:
          • James Ouellette, MD
        • Kontakt:
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic Foundation
        • Kontakt:
        • Ledende efterforsker:
          • Jaekeun Kim, MD
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The Ohio State University
        • Ledende efterforsker:
          • Mina Makary, MD
        • Kontakt:
    • Pennsylvania
      • Allentown, Pennsylvania, Forenede Stater, 18103
        • Rekruttering
        • Lehigh Valley Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Errin Hoffman, MD
    • Texas
      • Austin, Texas, Forenede Stater, 78705
        • Rekruttering
        • St. David's Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Shaun McKenzie, MD
    • Virginia
      • Richmond, Virginia, Forenede Stater, 23229
        • Rekruttering
        • Henrico Doctors' Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Laurie Cuttino, MD
    • Washington
      • Seattle, Washington, Forenede Stater, 98122
        • Afsluttet
        • Swedish Medical Center
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • University of Wisconsin
        • Kontakt:
        • Ledende efterforsker:
          • John Swietlik, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

22 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Sandsynlighedsprøve

Studiebefolkning

Subjects who are 22 years of age or older with a diagnosis of: primary (e.g., HCC, cholangiocarcinoma, angiosarcoma) or metastatic (from other primary cancers) liver cancer, or benign liver tumors (e.g., adenoma).

Beskrivelse

Inclusion Criteria:

  1. Subject is ≥22 years of age
  2. Subject has signed the Ethics Committee (EC), or Institutional Review Board (IRB) approved study Informed Consent Form (ICF) prior to any study related tests/procedures and is willing to comply with study procedures and required follow-up assessments
  3. Subject's liver tumor(s) can be partially or completely treated with histotripsy

Exclusion Criteria:

  1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the study period
  2. Subject is enrolled in an interventional HistoSonics-sponsored trial
  3. Subject has a concurrent condition that, in the investigator's opinion, could jeopardize the safety of the subject or compliance with the protocol

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
HistoSonics Edison System

Histotripsy with the HistoSonics Edison System for the full or partial destruction of liver tumors

Andre navne:
  • Histotripsi

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Histotripsy Technical Success
Tidsramme: ≤36 hours post-histotripsy treatment procedure

Histotripsy technical success, defined as completion of histotripsy on the target tumor(s) according to the histotripsy treatment plan, assessed by the treating physician on CT or MR imaging at ≤36 hours post-histotripsy treatment procedure. The histotripsy treatment plan will include identification of the intended complete or partial treatment of the tumor(s). The histotripsy treatment zone must provide target tumor coverage greater than or equal to the degree of treatment intended.

≤36 hours post-histotripsy treatment procedure

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

14. oktober 2024

Primær færdiggørelse (Anslået)

1. november 2034

Studieafslutning (Anslået)

1. november 2039

Datoer for studieregistrering

Først indsendt

27. juni 2024

Først indsendt, der opfyldte QC-kriterier

27. juni 2024

Først opslået (Faktiske)

3. juli 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • CSP3828

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .